New drug IBI363 aims to supercharge immune system against tough cancers
NCT ID NCT05290597
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. It is too soon to know if the drug will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI363 (a fusion protein that combines a modified IL-2 molecule with an anti-PD-1 antibody to stimulate immune cells and block a cancer defense)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced cancers or lymphomas that have not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 40 participants, so the main goal is safety, not effectiveness. The drug may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Care Wollongong
Sydney, New South Wales, 2500, Australia
-
Sydney, New South Wales, 2109, Australia
-
Sydney Southwest Private Hospital
Sydney, New South Wales, 2170, Australia
-
Westmead Hospital
Sydney, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink Hard-to-Treat cancers
- New drug combo targets tough cancers in early trial
- New drug duo aims to fight Hard-to-Treat cancers
- New pill shows promise in early cancer trial
- New drug cocktail shows promise against tough cancers
- New combo therapy shows promise for Hard-to-Treat cancers